Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice ; volume:10 ; number:1 ; day:16 ; month:1 ; year:2019 ; pages:1 ; date:12.2019
Nature Communications ; 10, Heft 1 (16.1.2019), 1, 12.2019
- Creator
-
Rossin, Raffaella
Versteegen, Ron M.
Wu, Jeremy
Khasanov, Alisher
Wessels, Hans J.
Steenbergen, Erik J.
Hoeve, Wolter ten
Janssen, Henk M.
Onzen, Arthur H. A. M. van
Hudson, Peter J.
Robillard, Marc S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-019-08376-x
- URN
-
urn:nbn:de:101:1-2019020111441081533049
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rossin, Raffaella
- Versteegen, Ron M.
- Wu, Jeremy
- Khasanov, Alisher
- Wessels, Hans J.
- Steenbergen, Erik J.
- Hoeve, Wolter ten
- Janssen, Henk M.
- Onzen, Arthur H. A. M. van
- Hudson, Peter J.
- Robillard, Marc S.
- SpringerLink (Online service)
Other Objects (12)
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein